Market Overview:
With the increasing demand for more reliable and effective clostridium difficile diagnostics tools, accurate and improved diagnostic methods for the various strains of this gram are in high demand. Many manufacturers are introducing new generation instruments for accurate detection of this gram in patients with chronic diarrhea and other conditions that may lead to the occurrence of clostridium difficile. Some of the newest and highly sophisticated diagnostic tools are designed to detect and measure parameters such as titer of acidophilus, stool culture, and DNA extraction. Another reason why this diagnostic test for clostridium difficile has gained popularity is that they are less expensive than other available technologies such as viral cultures and molecular probe test for this gram.
Get Sample Report with Latest Covid19 Impact Analysis @ https://www.coherentmarketinsights.com/insight/request-sample/1499
Competitive Landscape:
Major players operating in the global clostridium difficile diagnostics and treatment market include Olympus Corporation, F. Hoffmann-La Roche Ltd, Siemens Healthcare, Biochem Pharmaceutical Industries Ltd., Johnson & Johnson Services Inc., Abbott Laboratories, and Beckman Coulter Inc.
Key Market Drivers:
The global incidence of clostridium difficile is the major factor that is expected to drive the growth of the global clostridium difficile diagnostics and treatment market. For instance, according to the National Institutes of Health (NIH), the overall rate of clostridium difficile in 2018 was around 2.24 per 1000 admissions, annually and around 3.54 per 10000 patients every day yearly. A wide range of clinical applications of this diagnostic test has emerged over the last couple of years. For example, in patients with chronic diarrhea, RT PCR analysis and culture of feces from the patient’s immediate environment are used to diagnose various species of Clostridium. Additionally, point-of-care diagnostics for this gram can be used for monitoring acidophilus concentrations in various clinical settings. These diagnostic tests for this gram have also shown utility in other situations such as rheumatoid arthritis, sepsis, osteomyelitis, oral infections, and septicemia. The accuracy and utility of these point-of-care diagnostics have made them a suitable medical device for routine clinical use. The increasing launch of diagnostic tools by key market players is estimated to augment the growth of the global clostridium difficile diagnostics and treatment market.
Covid-19 Impact Analysis:
The COVID-19 pandemic has increasingly posed challenges for the growth of the global clostridium difficile diagnostics and treatment market, owing to the increasing incidence of COVID positive cases in the world. For instance, according to Our World in Data, in September 2020, the 7-day average of COVID positive cases in India was around 19,524.
Purchase This Premium Report To Access Full Information @ https://www.coherentmarketinsights.com/insight/buy-now/1499
Key Takeaways:
-
The size of the global clostridium difficile diagnostics and treatment market is estimated to increase at a CAGR of 8.2%, during the market forecast period, owing to the increasing prevalence of clostridium difficile in the world. For instance, according to the National Institutes of Health (NIH), the estimated rates for clostridium difficile with onset in IM or ICU wards in 2018 were around 10.80 and 11.08 per 1000 admissions respectively.
-
North America is expected to hold a major share of the global clostridium difficile diagnostics and treatment market, owing to the increasing prevalence of clostridium difficile in the region. For instance, according to the National Institutes of Health (NIH), the annual incidence of clostridium difficile in the U.S. is around 462,100 cases.
-
The Asia Pacific is estimated to witness high growth in the global clostridium difficile diagnostics and treatment market, owing to the prevalence of clostridium difficile in regions such as Malaysia and Thailand. For instance, according to the National Institutes of Health (NIH), the prevalence of clostridium difficile in Thailand ranges from 4.8% to 52.2%.
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837